Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 4.35 Million AUD | 17.93% |
| 2023 | 3.69 Million AUD | -15.49% |
| 2022 | 4.37 Million AUD | 203.8% |
| 2021 | 1.43 Million AUD | -45.04% |
| 2020 | 2.61 Million AUD | 75.23% |
| 2019 | 1.49 Million AUD | 2.73% |
| 2018 | 1.45 Million AUD | -4.91% |
| 2017 | 1.52 Million AUD | 8.73% |
| 2016 | 1.4 Million AUD | -20.11% |
| 2015 | 1.76 Million AUD | -64.08% |
| 2014 | 4.9 Million AUD | 91.38% |
| 2013 | 2.56 Million AUD | 25.61% |
| 2012 | 2.03 Million AUD | -3.28% |
| 2011 | 2.1 Million AUD | -17.7% |
| 2010 | 2.56 Million AUD | -46.51% |
| 2009 | 4.78 Million AUD | 44.42% |
| 2008 | 3.31 Million AUD | -18.12% |
| 2007 | 4.05 Million AUD | -3.01% |
| 2006 | 4.17 Million AUD | -35.85% |
| 2005 | 6.5 Million AUD | 22.35% |
| 2004 | 5.32 Million AUD | 79.25% |
| 2003 | 2.96 Million AUD | 59.17% |
| 2002 | 1.86 Million AUD | 15.24% |
| 2001 | 1.61 Million AUD | 27.42% |
| 2000 | 1.26 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.65 Million AUD | 0.0% |
| 2024 Q1 | 3.65 Million AUD | -1.05% |
| 2024 FY | 4.35 Million AUD | 17.93% |
| 2024 Q4 | 4.35 Million AUD | 0.0% |
| 2024 Q3 | 4.35 Million AUD | 19.19% |
| 2023 Q3 | 3.69 Million USD | -20.84% |
| 2023 Q4 | 3.69 Million AUD | 0.0% |
| 2023 FY | 3.69 Million AUD | -15.49% |
| 2023 Q1 | 4.66 Million USD | 6.76% |
| 2023 Q2 | 4.66 Million AUD | 0.0% |
| 2022 FY | 4.37 Million AUD | 203.8% |
| 2022 Q2 | 3.09 Million AUD | 0.0% |
| 2022 Q3 | 4.37 Million AUD | 41.39% |
| 2022 Q4 | 4.37 Million AUD | 0.0% |
| 2022 Q1 | 3.09 Million AUD | 114.87% |
| 2021 Q3 | 1.43 Million AUD | 5.58% |
| 2021 Q1 | 1.36 Million AUD | -47.94% |
| 2021 Q2 | 1.36 Million AUD | 0.0% |
| 2021 FY | 1.43 Million AUD | -45.04% |
| 2021 Q4 | 1.43 Million AUD | 0.0% |
| 2020 FY | 2.61 Million AUD | 75.23% |
| 2020 Q1 | 1.48 Million AUD | -0.84% |
| 2020 Q2 | 1.48 Million AUD | 0.0% |
| 2020 Q3 | 1.64 Million AUD | 10.74% |
| 2020 Q4 | 2.61 Million AUD | 59.57% |
| 2019 Q2 | 1.09 Million AUD | 9.14% |
| 2019 Q3 | 1.49 Million AUD | 36.09% |
| 2019 Q1 | 1 Million AUD | -30.87% |
| 2019 Q4 | 1.49 Million AUD | 0.05% |
| 2019 FY | 1.49 Million AUD | 2.73% |
| 2018 Q2 | 1.21 Million AUD | 2.59% |
| 2018 FY | 1.45 Million AUD | -4.91% |
| 2018 Q4 | 1.45 Million AUD | 0.23% |
| 2018 Q3 | 1.45 Million AUD | 19.58% |
| 2018 Q1 | 1.18 Million AUD | -22.67% |
| 2017 Q2 | 1.76 Million AUD | 3.94% |
| 2017 FY | 1.52 Million AUD | 8.73% |
| 2017 Q4 | 1.52 Million AUD | 4.36% |
| 2017 Q3 | 1.46 Million AUD | -17.08% |
| 2017 Q1 | 1.7 Million AUD | 20.87% |
| 2016 Q3 | 1.33 Million AUD | 7.9% |
| 2016 FY | 1.4 Million AUD | -20.11% |
| 2016 Q1 | 1.15 Million AUD | -34.47% |
| 2016 Q4 | 1.4 Million AUD | 5.58% |
| 2016 Q2 | 1.23 Million AUD | 7.03% |
| 2015 Q3 | 1.73 Million AUD | -44.9% |
| 2015 FY | 1.76 Million AUD | -64.08% |
| 2015 Q2 | 3.14 Million AUD | 0.0% |
| 2015 Q4 | 1.76 Million AUD | 1.46% |
| 2015 Q1 | 3.14 Million AUD | -35.76% |
| 2014 Q3 | 4.9 Million AUD | -38.11% |
| 2014 FY | 4.9 Million AUD | 91.38% |
| 2014 Q2 | 7.91 Million AUD | 0.0% |
| 2014 Q1 | 7.91 Million AUD | 209.2% |
| 2014 Q4 | 4.9 Million AUD | 0.0% |
| 2013 Q3 | 2.46 Million AUD | 29.38% |
| 2013 Q1 | 1.79 Million AUD | -11.99% |
| 2013 Q4 | 2.56 Million AUD | 3.9% |
| 2013 FY | 2.56 Million AUD | 25.61% |
| 2013 Q2 | 1.9 Million AUD | 6.17% |
| 2012 Q2 | 1.6 Million AUD | 0.0% |
| 2012 FY | 2.03 Million AUD | -3.28% |
| 2012 Q4 | 2.03 Million AUD | 0.0% |
| 2011 Q4 | 2.1 Million AUD | 0.0% |
| 2011 FY | 2.1 Million AUD | -17.7% |
| 2011 Q2 | 2.39 Million AUD | 0.0% |
| 2010 Q4 | 2.56 Million AUD | 0.0% |
| 2010 FY | 2.56 Million AUD | -46.51% |
| 2010 Q2 | 2.82 Million AUD | 0.0% |
| 2009 Q4 | 3.86 Million AUD | 0.0% |
| 2009 FY | 4.78 Million AUD | 44.42% |
| 2009 Q2 | 3.6 Million AUD | 0.0% |
| 2008 FY | 3.31 Million AUD | -18.12% |
| 2008 Q4 | 3.31 Million AUD | 0.0% |
| 2008 Q2 | 2.71 Million AUD | 0.0% |
| 2007 Q4 | 4.05 Million AUD | 0.0% |
| 2007 FY | 4.05 Million AUD | -3.01% |
| 2007 Q2 | 3.88 Million AUD | 0.0% |
| 2006 Q4 | 4.17 Million AUD | 0.0% |
| 2006 Q2 | 3.71 Million AUD | 0.0% |
| 2006 FY | 4.17 Million AUD | -35.85% |
| 2005 Q4 | 6.5 Million AUD | 0.0% |
| 2005 FY | 6.5 Million AUD | 22.35% |
| 2005 Q2 | 4.7 Million AUD | 0.0% |
| 2004 FY | 5.32 Million AUD | 79.25% |
| 2003 FY | 2.96 Million AUD | 59.17% |
| 2002 FY | 1.86 Million AUD | 15.24% |
| 2001 FY | 1.61 Million AUD | 27.42% |
| 2000 FY | 1.26 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 89.171% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | 50.381% |
| Aspira Women's Health Inc. | 8.62 Million USD | 49.506% |
| Biodesix, Inc. | 94.51 Million USD | 95.391% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -150.072% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -29.403% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -29.403% |
| Bionano Genomics, Inc. | 118.24 Million USD | 96.316% |
| CareDx, Inc | 223.28 Million USD | 98.049% |
| Check-Cap Ltd. | 1.33 Million USD | -227.527% |
| Castle Biosciences, Inc. | 86.54 Million USD | 94.966% |
| DarioHealth Corp. | 38.24 Million USD | 88.61% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.869% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 96.885% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.732% |
| ICON Public Limited Company | 7.74 Billion USD | 99.944% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.755% |
| Illumina, Inc. | 4.36 Billion USD | 99.9% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | 22.152% |
| iSpecimen Inc. | 6.07 Million USD | 28.331% |
| Standard BioTools Inc. | 159.86 Million USD | 97.275% |
| MDxHealth SA | 121.92 Million USD | 96.427% |
| 23andMe Holding Co. | 206.64 Million USD | 97.892% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 99.603% |
| Myriad Genetics, Inc. | 312.9 Million USD | 98.608% |
| Mainz Biomed B.V. | 12.15 Million USD | 64.176% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -297.761% |
| NeoGenomics, Inc. | 739.69 Million USD | 99.411% |
| Neogen Corporation | 1.44 Billion USD | 99.697% |
| Inotiv, Inc. | 588.04 Million USD | 99.259% |
| Natera, Inc. | 691.79 Million USD | 99.37% |
| OPKO Health, Inc. | 622.47 Million USD | 99.3% |
| Psychemedics Corporation | 6.59 Million USD | 33.978% |
| Prenetics Global Limited | 44.01 Million USD | 90.103% |
| Prenetics Global Limited | 44.01 Million USD | 90.103% |
| Precipio, Inc. | 3.67 Million USD | -18.63% |
| Personalis, Inc. | 95.65 Million USD | 95.446% |
| RadNet, Inc. | 2.07 Billion USD | 99.79% |
| Sera Prognostics, Inc. | 25.28 Million USD | 82.771% |
| Sotera Health Company | 2.68 Billion USD | 99.838% |
| Neuronetics, Inc. | 81.64 Million USD | 94.664% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 79.903% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 79.903% |
| Trinity Biotech plc | 83.38 Million USD | 94.776% |
| Twist Bioscience Corporation | 152.97 Million USD | 97.152% |
| Exagen Inc. | 34.25 Million USD | 87.281% |